The NHS cancer blood test trial, announced on 4 November 2026 and described by its backers as world-first, will assess whether a single blood sample can help GPs spot several cancers earlier in adults with abdominal symptoms. Led by the University of Birmingham, the study, called STRIDE-RCT, plans to recruit more than 20,000 patients at no fewer than 200 GP practices in England. It is research: the tests are being evaluated, and nothing in the announcement says they work or that they are a national screening service.
Key takeaways on the NHS cancer blood test trial
- STRIDE-RCT is a cluster platform trial run by the University of Birmingham, funded with up to £8.49 million by the Office for Life Sciences through the National Institute for Health and Care Research (NIHR).
- At least 200 GP practices in England and more than 20,000 NHS patients are expected to take part.
- Eligible patients are aged 45 or over and visit a GP with abdominal symptoms such as persistent bloating or discomfort.
- The tests look for signs of several cancers in one sample and suggest where in the body a cancer may have started.
- Thirteen cancer types are covered, from bowel and pancreatic to ovarian and prostate cancer.
- Whether the tests are accurate enough, and whether they should be used across the NHS, is what the trial is designed to find out.
How multi-cancer blood tests work
Tumours can shed traces into the bloodstream, including fragments of genetic material and proteins. A multi-cancer blood test measures such signals in one sample and tries to work out whether they point to a cancer and, if so, which organ is the likely source. According to the University of Birmingham, the tests in this trial use technologies including artificial intelligence and the measurement of blood proteins, and aim to find early markers before more severe symptoms develop. The announcement does not name the specific test or its developer, so we cannot describe its method in more detail.
Most participants will give one or two tubes of blood at their GP practice alongside routine blood tests. The result is intended to help the GP decide what to do next, in combination with the doctor’s own judgement.
Which cancers are being studied
| Group | Cancers named in the announcement |
|---|---|
| Digestive tract | Bowel, small bowel, stomach, oesophageal |
| Liver and pancreas | Pancreatic, liver, bile duct, gallbladder |
| Gynaecological | Ovarian, endometrial |
| Urinary and prostate | Kidney, bladder, prostate |
The grouping above is ours; the announcement lists the thirteen cancers without grouping them. It cites figures showing why the focus is on the abdomen: about 71,000 people in England are diagnosed with pancreatic, stomach, liver, ovarian or bowel cancer each year, and almost 35,000 die from these cancers annually. Some of these cancers are hard to spot because early symptoms are vague.
Why a trial and not a rollout
A test can look promising in small studies and still fail in routine care. The central questions are how often it correctly flags a cancer, how often it raises a false alarm, and whether earlier detection leads to better outcomes. Professor Aneel Bhangu, co-chief investigator and a colorectal surgeon, said the tests might help, but that the NHS needs to know for certain before using them across the health service. The trial will assess how the tests perform alongside GP judgement before any decision about a nationwide rollout.
What patients should know
- The test is not available as a routine NHS service. Taking part is through participating practices.
- Anyone with persistent abdominal symptoms should see their GP; the trial does not change that advice. See the Cancer Research UK site for general information on cancer symptoms.
- A negative result in a trial should not be read as a guarantee that no cancer is present.
Timeline
- 4 November 2026: the University of Birmingham announces the trial is being launched.
- Start date, recruitment period and end date: not stated in the announcement.
- After the trial: results will inform a decision on whether to use the tests more widely.
Market context: cancer diagnostics
Acumen Research And Consulting has no report specific to multi-cancer blood tests, so we cite its Cancer Diagnostics Market report as adjacent. It values the global market at USD 142.3 billion and projects USD 276.2 billion by 2032, a compound annual growth rate of 7.8% for 2024 to 2032. North America accounted for 41% of the market and Asia-Pacific is projected to grow at 8.5% a year.
The page gives the base year as 2022 in its summary and 2023 in its text, and the stated growth rate does not reconcile with its two endpoints; by our calculation, the endpoints imply roughly 6.9% to 7.6% a year depending on the base year. The report covers all cancer diagnostics and says nothing about this trial or about multi-cancer tests specifically.
Our analysis
In our assessment, the significance of STRIDE-RCT lies in its design and scale more than in any result, because none exists yet. Randomising practices to use the test or not, across more than 20,000 patients, is the kind of evidence needed to separate a promising technology from a useful one. The risk to watch is overstatement: headlines about a world-first trial can be read as proof of benefit, which the investigators themselves do not claim.
What is not disclosed
- The name of the test and its developer.
- The start date, duration and expected reporting date.
- The primary outcome and how success will be defined.
- How results will be shared with patients and GPs during the trial.
Risks and caveats
- The tests are under evaluation; their accuracy is unproven.
- False positives could cause anxiety and extra investigations; false negatives could falsely reassure.
- Market figures are adjacent, third-party projections.
- This article is news reporting and not medical advice.
What to watch next
- Recruitment progress across the 200 practices.
- Publication of the trial protocol and primary outcome.
- Identification of the test and evidence on its accuracy.
- Interim safety or process findings, if any.
General background
Read the original announcement at the University of Birmingham and learn about the health service at NHS England. For related coverage, see our reports on India’s healthcare investment trends and AI in drug development, and browse the Healthcare Services section.
Questions readers are asking about the NHS cancer blood test trial
Can I get the blood test on the NHS now?
No. It is being evaluated in a trial at participating practices and is not a routine service.
Does the test diagnose cancer?
The trial is assessing whether it can help flag cancers and suggest their origin; a diagnosis would still need further tests.
Who can take part?
Adults aged 45 and over who see a GP about abdominal symptoms at a participating practice.
FAQ
Who is funding the trial?
The Office for Life Sciences, through NIHR, with up to £8.49 million.
How many people will be enrolled?
More than 20,000 patients across at least 200 GP practices.
When will results be available?
The announcement does not say.
How we reported this: details come from the University of Birmingham announcement of 4 November 2026; market figures are attributed to Acumen Research And Consulting. Last updated 4 November 2026. This is news reporting and not medical advice.
